Lisata Therapeutics, Inc.
LSTA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | 100% | – | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -6,592.9% | – | -490.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -6,655.7% | – | -461% |
| EPS Diluted | -0.49 | -0.54 | -0.55 | -0.55 |
| % Growth | 9.3% | 1.8% | 0% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |